AVIR - Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy | Benzinga
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for hepatitis C virus (HCV).
What Happened: The company says that the initial data from the Phase 2 combination eight-week study showed a 98% sustained virologic response at week four (SVR4), exceeding the company's efficacy criterion of >90% for continuing the study.
Additionally, very rapid kinetics were observed in all 60 patients across genotypes with viral load near or below the lower limit of quantification (LLOQ) at four weeks of treatment, which is supportive of an eight-week treatment regimen for the combination of bemnifosbuvir and RZR.
All 60 patients achieved viral load below the lower limit of quantification (LLOQ) at the end of the ...